| Source: |
| Type: |
| A protein reported to play an important role in sensitizing cancer cells to apoptosis.
Death Receptor 5 (DR5), also known as TRAIL receptor 2, is a member of the tumor necrosis factor (TNF) receptor superfamily. It plays a crucial role in the apoptosis (programmed cell death) pathway, particularly in the context of cancer. DR5 is often overexpressed in various types of tumors, including breast, colon, and lung cancers. This overexpression can make cancer cells more susceptible to TRAIL-induced apoptosis. TNFRSF10B (TNF Receptor Superfamily Member 10B; TRAIL-R2; DR5) — Cell-surface death receptor for TRAIL/TNFSF10. TNFRSF10B contains an intracellular death domain and, upon ligand binding, recruits adaptor proteins including FADD to form a death-inducing signaling complex that activates caspase-8 and downstream extrinsic apoptosis. Typical modulation in cancer: ↑ TNFRSF10B/DR5 expression or activation is generally favorable because it can increase tumor-cell sensitivity to TRAIL-mediated apoptosis. Loss, downregulation, mutation, or impaired signaling through DR5 can contribute to apoptosis resistance. Some anticancer agents increase DR5 expression as part of their pro-apoptotic mechanism. Typical modulation in Alzheimer’s disease: No established Alzheimer’s disease-specific direction. Excessive death-receptor signaling could potentially contribute to neuronal apoptosis, but TNFRSF10B is not currently a core AD target. Typical mechanistic relationship: TRAIL/TNFSF10 → TNFRSF10B/DR5 activation → FADD recruitment → caspase-8 activation ↑ → caspase-3/7 activation ↑ → extrinsic apoptosis ↑. |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4526- | MAG, | HNK, | Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis |
| - | Review, | Var, | NA |
| 8717- | MeJa, | Methyl jasmonate induces apoptosis and pro-apoptotic autophagy via the ROS pathway in human non-small cell lung cancer |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | H157 | - | in-vitro, | Lung, | H1792 |
| 1777- | MLT, | Melatonin as an antioxidant: under promises but over delivers |
| - | Review, | Var, | NA |
| 8898- | MOR, | Molecular mechanism of anti-cancerous potential of Morin extracted from mulberry in Hela cells |
| - | in-vitro, | Cerv, | HeLa |
| 8874- | MOR, | The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives |
| - | Review, | Var, | NA |
| 8961- | mushLions, | A Novel Erinacine S Derivative from Hericium erinaceus Overcomes Chemoresistance in Colorectal Cancer Cells by Enhancing TRAIL/TNFR1/DR5 Expression through Histone Acetylation |
| - | in-vivo, | CRC, | NA |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 6487- | Nimb, | Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development |
| - | Review, | Var, | NA |
| 4957- | PEITC, | Phenethyl Isothiocyanate (PEITC) from Cruciferous Vegetables Targets Human Cancer Stem-Like Cells |
| - | vitro+vivo, | Cerv, | HeLa |
| 4960- | PEITC, | Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells |
| - | in-vivo, | Cerv, | HeLa |
| 4918- | PEITC, | Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights |
| - | Review, | Var, | NA |
| 5159- | PLB, | Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression |
| - | in-vitro, | AML, | K562 |
| 4967- | PSO, | Psoralidin's Anti-Cancer Mechanisms: A Technical Guide |
| - | Review, | Var, | NA |
| 3354- | QC, | Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine |
| - | Review, | Var, | NA |
| 3369- | QC, | Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects |
| - | Review, | Pca, | NA |
| 64- | QC, | Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | SW-620 | - | in-vitro, | Colon, | Caco-2 |
| 66- | QC, | Emerging impact of quercetin in the treatment of prostate cancer |
| - | Review, | Pca, | NA |
| 69- | QC, | Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 47- | QC, | Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells |
| - | in-vitro, | NSCLC, | H460 | - | in-vitro, | NSCLC, | A549 |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 914- | QC, | Quercetin and Cancer Chemoprevention |
| - | Review, | Var, | NA |
| 3098- | RES, | Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers |
| - | Review, | Var, | NA |
| 3061- | RES, | The Anticancer Effects of Resveratrol: Modulation of Transcription Factors |
| - | Review, | Var, | NA |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
| 1465- | SFN, | TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells |
| - | in-vitro, | Bladder, | NA |
| 1458- | SFN, | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
| - | Review, | Bladder, | NA |
| 3289- | SIL, | Silymarin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 2196- | SK, | Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species |
| - | Review, | Var, | NA |
| 1928- | TQ, | Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2123- | TQ, | Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma |
| - | in-vitro, | lymphoma, | PEL |
| 3427- | TQ, | Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets |
| - | in-vitro, | Var, | NA |
| 3790- | UA, | Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:88 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid